| abstract |
The present invention relates to double-stranded ribonucleic acid (dsRNA) for inhibiting expression of the subtilisin-kexin 9 proprotein convertase gene (PCSK9), where said dsRNA includes an antisense strand having a nucleotide sequence of less than 30 nucleotides in length, usually 19-25 nucleotides, and essentially complementary to at least part of the PCSK9 gene. The present invention also relates to a pharmaceutical composition comprising dsRNA in combination with a pharmaceutically acceptable carrier, and to methods of treating diseases caused by expression of the PCSK9 gene, using said pharmaceutical composition. |